Andrew P Barbour

List of Publications by Year
in descending order

79 papers	12,267 citations	136950 32 h-index	66911 78 g-index
82 all docs	82 docs citations	82 times ranked	17788 citing authors

#	Article	IF	Citations
1	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
2	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
3	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
4	Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, The, 2011, 12, 681-692.	10.7	1,467
5	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
6	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology, 2012, 142, 1021-1031.e15.	1.3	443
7	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics, 2016, 48, 1131-1141.	21.4	332
8	Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer, 2011, 47, 354-360.	2.8	300
9	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nature Communications, 2014, 5, 5224.	12.8	236
10	Adenocarcinoma of the Gastroesophageal Junction. Annals of Surgery, 2007, 246, 1-8.	4.2	203
11	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
12	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology, 2018, 68, 949-963.	7.3	106
13	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
14	Risk Stratification for Early Esophageal Adenocarcinoma: Analysis of Lymphatic Spread and Prognostic Factors. Annals of Surgical Oncology, 2010, 17, 2494-2502.	1.5	86
15	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine, 2015, 2, 671-680.	6.1	86
16	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
17	Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Annals of Surgical Oncology, 2007, 14, 306-316.	1.5	71
18	Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. Annals of Surgical Oncology, 2008, 15, 2894-2902.	1.5	68

#	Article	IF	Citations
19	BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy. European Journal of Cancer, 2014, 50, 2668-2676.	2.8	67
20	Endoscopic Ultrasound Predicts Outcomes for Patients with Adenocarcinoma of the Gastroesophageal Junction. Journal of the American College of Surgeons, 2007, 205, 593-601.	0.5	59
21	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell and Melanoma Research, 2015, 28, 254-266.	3.3	59
22	Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. Psycho-Oncology, 2015, 24, 763-770.	2.3	49
23	Defining Cure for Esophageal Cancer: Analysis of Actual 5-Year Survivors Following Esophagectomy. Annals of Surgical Oncology, 2011, 18, 1766-1774.	1.5	46
24	Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis, 2016, 37, 356-365.	2.8	46
25	Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Annals of Surgical Oncology, 2016, 23, 1096-1103.	1.5	43
26	Thoracoscopic-Assisted Esophagectomy for Esophageal Cancer. Annals of Surgery, 2010, 252, 281-291.	4.2	42
27	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Practical Radiation Oncology, 2020, 10, e136-e146.	2.1	41
28	Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surgery, 2021, 156, 836.	4.3	41
29	Genomeâ€wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. Genes Chromosomes and Cancer, 2014, 53, 324-338.	2.8	38
30	Long-term Health-related Quality of Life Following Esophagectomy. Annals of Surgery, 2017, 265, 1158-1165.	4.2	38
31	Isolated Limb Infusion for Malignant Melanoma: Predictors of Response and Outcome. Annals of Surgical Oncology, 2009, 16, 3463-3472.	1.5	37
32	Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma. Molecular and Cellular Proteomics, 2015, 14, 3023-3039.	3.8	33
33	Intralesional PVâ€10 for the treatment of inâ€transit melanoma metastasesâ€”Results of a prospective, nonâ€randomized, single center study. Journal of Surgical Oncology, 2018, 117, 579-587.	1.7	30
34	Early Diagnostic Biomarkers for Esophageal Adenocarcinomaâ€”The Current State of Play. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1185-1209.	2.5	29
35	Role of human papillomaviruses in esophageal squamous cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 12-28.	1.1	27
36	Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. Journal of Surgical Oncology, 2015, 112, 359-365.	1.7	27

#	Article	IF	Citations
37	Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Gastroenterology, 2022, 162, 320-324.e4.	1.3	26
38	Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus. Molecular and Cellular Proteomics, 2018, 17, 2324-2334.	3.8	25
39	Human CD141⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. , 2021, 9, e001963.		25
40	Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. European Journal of Cancer, 2014, 50, 1301-1309.	2.8	24
41	Australian multiâ€center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. Journal of Surgical Oncology, 2014, 109, 780-785.	1.7	23
42	Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics, 2020, 10, 4116-4133.	10.0	23
43	Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ Journal of Surgery, 2017, 87, 44-48.	0.7	20
44	Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 2018, 117, 1687-1696.	1.7	20
45	Complex structural rearrangements are present in high-grade dysplastic Barrettâ€™s oesophagus samples. BMC Medical Genomics, 2019, 12, 31.	1.5	19
46	Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy. International Journal of Surgery, 2018, 53, 86-92.	2.7	17
47	Primary cutaneous melanoma of the scalp: Patterns of recurrence. Journal of Surgical Oncology, 2017, 115, 449-454.	1.7	16
48	Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Annals of Surgical Oncology, 2017, 24, 3245-3251.	1.5	16
49	The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2375-2384.	1.5	16
50	Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome. International Journal of Cancer, 2013, 133, 3000-3007.	5.1	14
51	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. Medical Journal of Australia, 2016, 204, 419-422.	1.7	14
52	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 2020, 10, 17687.	3.3	14
53	An innovative approach for locally advanced stage III cutaneous melanoma. Melanoma Research, 2012, 22, 257-262.	1.2	13
54	Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer, 2014, 17, 152-160.	5.3	12

#	Article	IF	Citations
55	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the â€˜Australian guidelines for the management of cutaneous melanomaâ€™. Australasian Journal of Dermatology, 2017, 58, 274-277.	0.7	12
56	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	2.6	12
57	Modeling the Cost-effectiveness of Strategies for Treating Esophageal Adenocarcinoma and High-grade Dysplasia. Journal of Gastrointestinal Surgery, 2012, 16, 1451-1461.	1.7	11
58	Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?. Annals of Surgical Oncology, 2015, 22, 4052-4059.	1.5	10
59	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	1.5	10
60	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	1.0	8
61	Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma. International Journal of Cancer, 2016, 139, 664-672.	5.1	7
62	Surgical management in patients with pancreatic cancer: a <scp>Q</scp>ueensland perspective. ANZ Journal of Surgery, 2013, 83, 859-864.	0.7	6
63	A Case-Control Study of the Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma in Australia. Journal of Oncology, 2014, 2014, 1-7.	1.3	6
64	Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 216-227.	1.1	6
65	Glyco-centric lectin magnetic bead array (LeMBA) â^' proteomics dataset of human serum samples from healthy, Barrett×³s esophagus and esophageal adenocarcinoma individuals. Data in Brief, 2016, 7, 1058-1062.	1.0	6
66	Elevation of fatty acid desaturaseÂ2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acidâ€induced DNA damage. Clinical and Translational Medicine, 2022, 12, e810.	4.0	6
67	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. Journal of Clinical Oncology, 2015, 33, 4115-4115.	1.6	5
68	qmotif: determination of telomere content from whole-genome sequence data. Bioinformatics Advances, 2022, 2, .	2.4	5
69	Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. European Journal of Surgical Oncology, 2019, 45, 832-837.	1.0	4
70	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. Cancer Treatment Reviews, 2021, 98, 102219.	7.7	4
71	ROR1 and ROR2 expression in pancreatic cancer. BMC Cancer, 2021, 21, 1199.	2.6	4
72	C5b-9 Membrane Attack Complex Formation andÂExtracellular Vesicle Shedding in Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Frontiers in Immunology, 2022, 13, 842023.	4.8	4

#	Article	IF	Citations
73	Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key?. ANZ Journal of Surgery, 2012, 82, 599-606.	0.7	2
74	Two cases of <scp>NSAID</scp>â€induced gastropathy and enteropathy of the ileum. ANZ Journal of Surgery, 2015, 85, 584-585.	0.7	1
75	To BE or not to BE: non-invasive screening for Barrettâ€™s esophagus, dysplasia and adenocarcinoma. Translational Gastroenterology and Hepatology, 2019, 4, 31-31.	3.0	1
76	Patients with inâ€transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PVâ€10â€”A propensity score matched, single center study. Journal of Surgical Oncology, 2019, 119, 717-727.	1.7	1
77	Consideration of Mesh-Related Complications. Annals of the Royal College of Surgeons of England, 2008, 90, 175-176.	0.6	1
78	Breaking bad conduits: â€˜resleevingâ€™ the intrathoracic gastric conduit post oesophagectomy. ANZ Journal of Surgery, 2018, 88, E222-E223.	0.7	0
79	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	2.4	0